Alteogen’s ‘similarity’ for Eylea biosimilar with the original medicine

Published: 2018-01-18 16:19:03

Updated: 2018-01-18 16:19:03

Alteogen(CEO Soon-Jae Park), an antibody biosimilar company, announced the company has secured ‘similarity’ for the Eylea biosimilar(ALT-L9) with the original medicine at a U.S. nonclinical trial and ended it without any particular adverse drug reaction.

According to Alteogen, the company has carried out a repeated toxicity test for Eylea and ALT0L9 on monkeys by administering it once 4 weeks ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.